Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group, according to a statement reviewed by Bloomberg News. The deal is expected to be accretive earnings per share about 12 months after it closes, and will “accelerate innovation and support long-term value creation for our shareholders,” Agilent Chief Executive Officer
With more than 300 specialized antibodies, Biocare, based in the San Francisco Bay ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.